Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer
View: Text | PDF
Research Article Microbiology Pulmonology

Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis

  • Text
  • PDF
Abstract

Pulmonary fibrosis is a chronic and often fatal disease. The pathogenesis is characterized by aberrant repair of lung parenchyma, resulting in loss of physiological homeostasis, respiratory failure, and death. The immune response in pulmonary fibrosis is dysregulated. The gut microbiome is a key regulator of immunity. The role of the gut microbiome in regulating the pulmonary immunity in lung fibrosis is poorly understood. Here, we determine the impact of gut microbiota on pulmonary fibrosis in substrains of C57BL/6 mice derived from different vendors (C57BL/6J and C57BL/6NCrl). We used germ-free models, fecal microbiota transplantation, and cohousing to transmit gut microbiota. Metagenomic studies of feces established keystone species between substrains. Pulmonary fibrosis was microbiota dependent in C57BL/6 mice. Gut microbiota were distinct by β diversity and α diversity. Mortality and lung fibrosis were attenuated in C57BL/6NCrl mice. Elevated CD4+IL-10+ T cells and lower IL-6 occurred in C57BL/6NCrl mice. Horizontal transmission of microbiota by cohousing attenuated mortality in C57BL/6J mice and promoted a transcriptionally altered pulmonary immunity. Temporal changes in lung and gut microbiota demonstrated that gut microbiota contributed largely to immunological phenotype. Key regulatory gut microbiota contributed to lung fibrosis, generating rationale for human studies.

Authors

Stephen J. Gurczynski, Jay H. Lipinski, Joshua Strauss, Shafiul Alam, Gary B. Huffnagle, Piyush Ranjan, Lucy H. Kennedy, Bethany B. Moore, David N. O’Dwyer

×

Figure 1

Lung fibrosis is heterogenous and microbiota dependent in substrain C57BL/6 mice.

Options: View larger image (or click on image) Download as PowerPoint
Lung fibrosis is heterogenous and microbiota dependent in substrain C57B...
Here, we examined lung fibrosis in C57BL/6 substrain experimental mice (C57BL/6J, JAX, and C57BL/6NCrl, CR). (A) JAX mice are more susceptible to weight loss after acute lung injury from bleomycin compared with CR mice. (B) JAX mice exhibit increased mortality after bleomycin compared with CR mice (log rank P < 0.0001) (JAX mortality 70%, CR mortality 5%). (C) JAX mice demonstrate significantly higher levels of lung fibrosis day 21 after bleomycin compared with CR mice (P < 0.05) measured by lung hydroxyproline content. (D) Gut microbiota depletion using broad-spectrum oral antibiotics results in significant protection for JAX mice from bleomycin-induced mortality (log rank P = 0.006). (E) Lung fibrosis is reduced in JAX mice treated with antibiotics (1 surviving mouse in control group) and CR mice treated with antibiotics. (F) Lung fibrosis is reduced in germ-free (GF) CR mice compared with conventional specific pathogen–free (SPF) CR mice. (G and H) Pulmonary interleukin-6 (IL-6) and leukemia inhibitory factor (LIF), a member of the IL-6 superfamily, are attenuated after bleomycin in CR mice compared with JAX. (I) Alveolar injury measured by IgM in bronchoalveolar lavage fluid day 7 after bleomycin is attenuated in CR mice compared with JAX mice. (A–C n = 20 per group, D and E n = 10 per group, F n = 5–6 per group, G and H n = 20 per group, I n = 10 per group.) Kaplan-Meier (KM) survival estimates and log rank test where applicable (B and D), unpaired t test or Mann-Whitney test (C and F–I), ANOVA (E), multiple t tests per row with correction for multiple comparison where applicable (A). *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts